Osteonecrosis of the Jaw Is Rare With Denosumab for Bone Loss
(MedPage Today) -- Study finds risk very low, even with long-term drug therapy. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - November 20, 2014 Category: Endocrinology Source Type: news
Infection Risk Seen as Minimal With Denosumab
(MedPage Today) -- No increased risk whether administered alone or with DMARDs. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - November 18, 2014 Category: Geriatrics Source Type: news
Denosumab After Teriparatide Boosts Bone-Density Gains Denosumab After Teriparatide Boosts Bone-Density Gains
Newly reported data should guide clinicians as they make initial osteoporosis-treatment decisions, researchers say. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Romosozumab Benefits Sustained After Transition to DenosumabRomosozumab Benefits Sustained After Transition to Denosumab
Improvements previously seen in 1 year data on the antisclerostin antibody continue with 2 years of treatment and with transition to denosumab in year 3. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Review Examines Efficacy and Safety of Osteoporosis Drugs (FREE)
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
Bisphosphonates, denosumab, teriparatide, and raloxifene all reduce risk for fracture relative to placebo in women with osteoporosis, according to a federally commissioned systematic review … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 9, 2014 Category: Primary Care Source Type: news
CHMP Gives Nod to New Drugs in Cancer CareCHMP Gives Nod to New Drugs in Cancer Care
Marketing authorization has been granted in Europe for generic versions of busulfan and filgrastim and for expanded use of denosumab. News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 28, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Comparison of side effects, efficacy of osteoporosis drugs
A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms. These findings were presented recently at the American Society for Bone and Mineral Research's annual meeting. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 5, 2013 Category: Consumer Health News Tags: Bones / Orthopedics Source Type: news
Osteoporosis drugs compared for side effects, efficacy in Loyola study
(Loyola University Health System) A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 2, 2013 Category: Global & Universal Source Type: news
Clinical Trial Underway of Drug to Prevent Skeletal-Related Events in Myeloma
The drug denosumab is approved for the prevention of skeletal-related events in patients with bone metastases from solid tumors, but its effects in patients with multiple myeloma need to be further studied. The drug is a fully human monoclonal antibody against RANK ligand, a protein critical for osteoclast formation, maturation, and function. An international clinical trial of denosumab is underway to help determine if it can prevent skeletal-related events in myeloma. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - October 25, 2013 Category: Hematology Source Type: news
Osteoporosis Drug Denosumab Shows Benefit to 8 YearsOsteoporosis Drug Denosumab Shows Benefit to 8 Years
The FREEDOM Extension study shows a prolonged effect of treatment with the osteoporosis drug denosumab out to 8 years of therapy, albeit with caveats that could explain some of these findings. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 15, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Combo Therapy Sustains Bone-Density ImprovementsCombo Therapy Sustains Bone-Density Improvements
Two-year results of a combination of denosumab and teriparatide therapy show sustained improvements in bone-mineral density that exceed that expected with either drug alone. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 9, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Denosumab Most Effective in High-Risk Prostate Cancer Patients
The anti-RANKL antibody denosumab is more effective for preventing bone metastasis in men with high-risk castration-resistant prostate cancer compared with low-risk disease, according to results of a new study. (Source: Cancer Network)
Source: Cancer Network - October 2, 2013 Category: Cancer & Oncology Source Type: news
Denosumab Effective for Refractory Hypercalcemia of MalignancyDenosumab Effective for Refractory Hypercalcemia of Malignancy
Denosumab appears to reduce hypercalcemia of malignancy (HCM) that doesn't resolve with bisphosphonates, according to a planned interim analysis of an ongoing open-label proof of concept study. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Denosumab shows favorable results in FREEDOM extension
Read the full story on MD Consult:
Denosumab shows favorable results in FREEDOM extension (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - August 2, 2013 Category: Journals (General) Source Type: news
Denosumab: Nonsurgery Option for Giant Cell Tumor of BoneDenosumab: Nonsurgery Option for Giant Cell Tumor of Bone
Safety and efficacy data from a phase 2 study of denosumab have been published, weeks after the US Food and Drug Administration expanded its use to include the treatment of giant cell tumor of bone. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 25, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
